Ligand Pharmaceuticals | LGND - Interest Expense On Debt


Ligand Pharmaceuticals reported $1.78M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agenus USD 16.02M 2.85M Dec/2025
Amgen USD 657M 4M Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
Baxter International USD 58M 14M Sep/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Enviri Corporation USD 28.44M 1.74M Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.08M 517K Mar/2026
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 479M 67M Mar/2026
Pacira USD 3.7M 193K Mar/2026
Pfizer USD 671M 40M Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023